Gene therapy for Stargardt disease (VG801)
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests a new gene therapy called VG801 for people with Stargardt disease, a genetic condition that causes vision loss. The treatment aims to improve or slow vision loss by delivering a working copy of the ABCA4 gene to the retina.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Stargardt disease (a type of inherited vision loss).
- You must have a genetic test showing changes in the ABCA4 gene.
- You must be at least 6 years old.
- Your study eye must have poor vision.
- You cannot have other eye diseases like glaucoma, uveitis, or diabetic retinopathy.
- You cannot have had gene therapy or eye surgery in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medicine called ACDN-01 for people with Stargardt retinopathy caused by ABCA4 gene mutations. The goal is to see if it can slow or stop vision loss in an eye with already damaged central vision.
This prescreening study looks for people with a specific genetic eye condition called Stargardt disease to see if they might be able to join a future trial for a new treatment called ACDN-01.
This study tests a new gene therapy called HG005 for Stargardt disease in young people aged 6 to 17. It aims to see if the treatment is safe and tolerable, and how well it works.
This trial tests a new gene therapy, AAVB-039, for people with Stargardt disease caused by a specific gene mutation. The treatment is given during eye surgery and aims to slow or stop vision loss.
This trial tests a new gene therapy called ZVS106e for people with inherited retinal degeneration caused by changes in both copies of the ABCA4 gene. The therapy aims to slow or stop vision loss, and the study will check if it is safe and if it works.
This trial tests a new gene therapy called SB-007 for people with Stargardt disease (STGD1). It is given as an injection under the retina to see if it is safe and can help slow vision loss.
Hear when a new Stargardt Disease 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.